# Medical Oncology Referral

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Audre Lorde (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML016-SYN-TD
- Date: 1979-03-09
- Fictional facility: St. Posthumous Health Center
- Fictional author: Naomi Fairweather, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- To: Beatriz Lozano, MD, Medical Oncology
- Urgency: Routine, within four weeks

## Referral question

Woman of 45, five and a half months after right total mastectomy for stage IA hormone receptor-positive, HER2-negative breast cancer, on tamoxifen since one month after surgery and now moving her survivorship care to primary care at this center. Please review the adjuvant endocrine plan and advise on hot flashes, surveillance, and genetic assessment, so that we can share her follow-up. **S**

## Questions for the consultant

1. Is tamoxifen alone the right adjuvant endocrine therapy for her, or is ovarian function suppression or an aromatase inhibitor indicated, and for how long?
2. How should her hot flashes be managed safely alongside tamoxifen?
3. What surveillance does she need, and are any blood tests, tumor markers, or scans indicated?
4. Should she have germline genetic testing now, and would a result change her care?
5. What should primary care monitor on tamoxifen, and how should we share her follow-up?

## Pertinent history

Right breast lump found at self-examination last September. Diagnostic mammogram and ultrasound: 1.6 cm mass, BI-RADS 5, normal axillary nodes. Core biopsy: invasive ductal carcinoma, grade 2, ER 90 percent, PR 60 percent, HER2 1+, Ki-67 12 percent. Right total mastectomy with flat closure and sentinel node biopsy: 1.6 cm, margins clear, 0 of 2 nodes, pT1c pN0(sn), stage IA; recurrence score 14. No chemotherapy or radiation. Tamoxifen 20 mg daily since late October. Premenopausal, with regular cycles. Mild hot flashes three or four times a day. No other medicines; no known allergy. PHQ-9 4, GAD-7 3. Germline testing was not offered at diagnosis. She chose not to have reconstruction and does not wish to wear an external prosthesis; she asks that this be respected and not revisited unless she raises it. She wants complete information and makes her own decisions. **S**

- Audre Lorde was born Audrey Geraldine Lorde on February 18, 1934, in New York City; her parents were immigrants from Grenada. **D**
- Lorde was a poet, essayist, and novelist. In her poetry and prose she wrote about matters important to her as a woman of color, as a lesbian, as a mother, and as a feminist; a reference biography describes her as an African American lesbian feminist and poet. **D**
- In 1977 a doctor found a tumor in Lorde's breast that, after about three weeks of uncertainty, proved benign. In a talk given that year to the Modern Language Association she said: "Your silence will not protect you." **D**
- On Labor Day 1978, during a routine self-examination, Lorde found a lump in her right breast; a diagnosis of malignancy and a mastectomy followed. She described the experience in The Cancer Journals. **D**
- After her mastectomy Lorde chose never to hide the fact of her missing breast. She refused to wear the "wad of lambswool pressed into a pale pink breast-shaped pad" pushed on her by nurses and medical counselors, and she was repeatedly scolded for posing a threat to cancer patient "morale." **D**

4 later historical claims are omitted because they describe events after the index age. See the teaching note.

Baseline: PHQ-9: 4; GAD-7: 3. All results are synthetic.

BP 124/78 mmHg; pulse 74 bpm; respirations 14/min; temperature 36.7 °C; oxygen saturation 99% on room air; weight 72 kg; BMI 25.5 kg/m². All vital signs are synthetic.

## Current medications

- Tamoxifen 20 mg oral tablet, one tablet by mouth once daily, planned for at least five years **S**

## Plan so far

- Tamoxifen 20 mg daily for at least five years, with questions at every visit about hot flashes, abnormal vaginal bleeding, and leg swelling or breathlessness, and a yearly gynecologic assessment. Guideline: Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update (2019); CMID: Clinical Monitoring Intelligence Database, breast cancer monograph (2026) **S**
- Lymphedema risk counseling and arm checks at every visit; bone health by calcium and vitamin D from diet and weight-bearing exercise; distress, depression, and anxiety screening at intervals. Guideline: American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. CA Cancer J Clin 2016;66(1):43-73 (2016); CMID: Clinical Monitoring Intelligence Database, breast cancer monograph (2026) **S**
- Written survivorship care plan, at least 150 minutes of activity a week, alcohol at or below one drink a day, and her decisions about reconstruction and a prosthesis recorded and respected. Guideline: American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. CA Cancer J Clin 2016;66(1):43-73 (2016); CMID: Clinical Monitoring Intelligence Database, breast cancer monograph (2026) **S**
